Nanobiotix SA (NANO) - Product Pipeline Analysis, 2018 Update

Summary

Nanobiotix SA (Nanobiotix) is a late stage clinical company which develops nanomedicines for the treatment of cancers. The company develops first-in-class products utilizing its proprietary technology NanoXray, based on the physical mode of action of nanoparticles that increase the X-rays dose energy absorption within tumor cells, without increasing the dose to the surrounding healthy tissues. Its lead product candidate NBTXR3, a cancer immunotherapy nanoparticles activated with radiotherapy is develped to destroy tumors and metastasis through immunogenic cell death leading to activation of the immune system. The company works in collaboration with Providence Cancer Institute, Weill Cornell Medicine and PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. It has operations with offices in the US, Spain and Germany. The company is a spin-off from the State University of New York (SUNY). Nanobiotix is headquartered in Paris, France.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Nanobiotix SA
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Nanobiotix SA Company Overview
Nanobiotix SA Company Snapshot
Nanobiotix SA Pipeline Products and Ongoing Clinical Trials Overview
Nanobiotix SA – Pipeline Analysis Overview
Nanobiotix SA - Key Facts
Nanobiotix SA - Major Products and Services
Nanobiotix SA Pipeline Products by Development Stage
Nanobiotix SA Ongoing Clinical Trials by Trial Status
Nanobiotix SA Pipeline Products Overview
NanoMag
NanoMag Product Overview
NanoPDT
NanoPDT Product Overview
NBTXR3 - Head & Neck Cancer
NBTXR3 - Head & Neck Cancer Product Overview
NBTXR3 - Head & Neck Cancer Clinical Trial
NBTXR3 - Liver Cancer
NBTXR3 - Liver Cancer Product Overview
NBTXR3 - Liver Cancer Clinical Trial
NBTXR3 - Lung Cancer
NBTXR3 - Lung Cancer Product Overview
NBTXR3 - Pancreatic Cancer
NBTXR3 - Pancreatic Cancer Product Overview
NBTXR3 - Prostate Cancer
NBTXR3 - Prostate Cancer Product Overview
NBTXR3 - Prostate Cancer Clinical Trial
NBTXR3 - Rectal Cancer
NBTXR3 - Rectal Cancer Product Overview
NBTXR3 - Rectal Cancer Clinical Trial
NBTXR3 - Soft Tissue Sarcoma
NBTXR3 - Soft Tissue Sarcoma Product Overview
NBTXR3 - Soft Tissue Sarcoma Clinical Trial
Nanobiotix SA - Key Competitors
Nanobiotix SA - Key Employees
Nanobiotix SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nanobiotix SA, Recent Developments
Apr 17, 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway
Jan 22, 2018: Nanobiotix Presents First Promising Data From Phase I/II Liver Cancers Trial Of NBTXR3 At The American Society Of Clinical Oncology Gastrointestinal Annual Meeting
Jan 11, 2018: NANOBIOTIX partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
Dec 26, 2017: FDA Approves Nanobiotix's First Immuno-Oncology Trial
Nov 13, 2017: NANOBIOTIX presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting
Nov 09, 2017: NANOBIOTIX provides update on the global development of its lead product NBTXR3
Nov 09, 2017: Nanobiotix provides update on the global development of its lead product NBTXR3
Oct 23, 2017: Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
Oct 23, 2017: Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
Sep 28, 2017: NANOBIOTIX plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Nanobiotix SA Pipeline Products and Ongoing Clinical Trials Overview
Nanobiotix SA Pipeline Products by Equipment Type
Nanobiotix SA Pipeline Products by Indication
Nanobiotix SA Ongoing Clinical Trials by Trial Status
Nanobiotix SA, Key Facts
Nanobiotix SA, Major Products and Services
Nanobiotix SA Number of Pipeline Products by Development Stage
Nanobiotix SA Pipeline Products Summary by Development Stage
Nanobiotix SA Ongoing Clinical Trials by Trial Status
Nanobiotix SA Ongoing Clinical Trials Summary
NanoMag - Product Status
NanoMag - Product Description
NanoPDT - Product Status
NanoPDT - Product Description
NBTXR3 - Head & Neck Cancer - Product Status
NBTXR3 - Head & Neck Cancer - Product Description
NBTXR3 - Head & Neck Cancer - A Phase Ib/II Study of PEP503 (Radioenhancer) with Radiotherapy in Combination with Concurrent Chemotherapy for Patients with Head and Neck Cancer
NBTXR3 - Head & Neck Cancer - A Study to Evaluate the Ability of NBTXR3 in Combination with Checkpoint Inhibitors in Lung and Head and Neck Cancer Patients
NBTXR3 - Head & Neck Cancer - PhI Study of NBTXR3 with Intensity Modulated Radiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
NBTXR3 - Liver Cancer - Product Status
NBTXR3 - Liver Cancer - Product Description
NBTXR3 - Liver Cancer - A Phase I-II Study of NBTXR3 Activated by Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Cancers
NBTXR3 - Lung Cancer - Product Status
NBTXR3 - Lung Cancer - Product Description
NBTXR3 - Pancreatic Cancer - Product Status
NBTXR3 - Pancreatic Cancer - Product Description
NBTXR3 - Prostate Cancer - Product Status
NBTXR3 - Prostate Cancer - Product Description
NBTXR3 - Prostate Cancer - A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT with Brachytherapy in Patients with Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated with Androgen Deprivation
NBTXR3 - Rectal Cancer - Product Status
NBTXR3 - Rectal Cancer - Product Description
NBTXR3 - Rectal Cancer - A Phase Ib/II Study of PEP503 (Radioenhancer) with Radiotherapy, in Combination with Concurrent Chemotherapy for Patients with Locally Advanced or Unresectable Rectal Cancer
NBTXR3 - Soft Tissue Sarcoma - Product Status
NBTXR3 - Soft Tissue Sarcoma - Product Description
NBTXR3 - Soft Tissue Sarcoma - Multicenter, Randomized, Open-label Phase II/III Study, to Compare Efficacy of NBTXR3 Implanted as Intratumor Injection and Activated by Radiotherapy versus Radiotherapy Alone in Patients with Locally Advanced Soft Tissue Sarcoma (Extremity and Trunk Wall)
Nanobiotix SA, Key Employees
Nanobiotix SA, Subsidiaries
Glossary
List of Figures
Nanobiotix SA Pipeline Products by Equipment Type
Nanobiotix SA Pipeline Products by Development Stage
Nanobiotix SA Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook